If you have a business interest in North American Adoptive T-Cell Therapies, or looking to network with senior executives and influencers within the space, learn more about the North American Adoptive T-Cell Therapies, taking place this June 28-30, 2016, at the Seaport Hotel & Seaport World Trade Center, Boston, US.

Here’s a quick look at the North American Adoptive T-Cell Therapies Congress Day One Agenda:

For the full speaker list with session details, download the full brochure now.

download-btn-sld

Time of Session
Title of Session
Session Speakers
8.30 Registration for All Attendees
8:50
Chairperson’s Opening of Conference
9:00
CAR T-Cell TargetingJan Joseph (Jos) Melenhorst, Director, Product Development & Correlative Sciences Laboratory, UNIVERSITY OF PENNSYLVANIA
9:30
TCRs in ImmunotherapyAndrew Sewell, Cardiff Institute of Infection & Immunity, UK
10:00
Biomarkers and T-Cell TherapyMichael Kalos, Chief Scientific Officer, Cancer Immunobiology at ELI LILLY AND COMPANY
10:30
Morning Networking Break: Coffee, Tea & Refreshments
11:00
Controlling CAR-T-Cell safety and efficacy using molecular switchesPeter Hoang, SVP, Business Development and Strategy, BELLICUM PHARMACEUTICALS
11:30
Panel Discussion: Safety Concerns in T-cell TherapyModerator:
Peter Hoang, SVP, Business Development and Strategy, BELLICUM PHARMACEUTICALS
Panelists:
Jan Joseph (Jos) Melenhorst, Director, Product Development & Correlative Sciences laboratory, UNIVERSITY OF PENNSYLVANIA
Michael Kalos, Chief Scientific Officer, Cancer Immunobiology at ELI LILLY AND COMPANY
Andrew Sewell, Cardiff University, UK
12:30
Networking Lunch
14:00
Adaptimmune – Transforming T-Cell TherapyAndrew Gerry, Director of Preclinical Research, ADAPTIMMUNE
14:30
Tumor Infiltrating Lymphocytes for Metastatic Cutaneous and Non-Cutaneous MelanomaRobert Hawkins, CEO, CELLULAR THERAPEUTICS LTD.
15:00
Engineering Best in Class T-Cells to Treat CancersYangbing Zhao, University of Pennsylvania, USA
15:30
Afternoon Networking Break: Coffee, Tea & Refreshments
16:00
Allogeneic Models in Adoptive T-Cell TherapySicco Popma, Scientific Director and leader of Gene-Modified Cell Therapies at JBIO (JANSSEN R&D)
16:30
PANEL DISCUSSION: Pre-Clinical Trial Decision MakingModerator:
Robert Hawkins, CEO, CELLULAR THERAPEUTICS LTD.

Panelists:
Sicco Popma, Scientific Director and leader of Gene-Modified Cell Therapies at JBIO (JANSSEN R&D)
Andrew Gerry, Director of Preclinical Research, ADAPTIMMUNE
Yangbing Zhao, University of Pennsylvania, USA
16:45 - 17:15
Cancer Immunotherapy and Gene TherapyChiara Bonini, Experimental Hematology, SAN RAFFAELE SCIENTIFIC INSTITUTE

For the full speaker list with session details, download the full brochure now.

download-btn-sld